Biological Response Modifiers Advisory Committee
Executive Summary
July 22-23 meeting is cancelled and will be rescheduled for autumn. National Cancer Institute researcher Steven Rosenberg recently indicated that Cetus' Proleukin (interleukin-2) for renal cell carcinoma might be on the committee's agenda ("The Pink Sheet" May 27, In Brief); IL-2 failed to clear the committee nearly a year ago ("The Pink Sheet" Aug. 6, p. 6).